Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas by Lindblad, M et al.
Hormone replacement therapy and risks of oesophageal and
gastric adenocarcinomas
M Lindblad*,1, LA Garcı ´a Rodrı ´guez
2, E Chandanos
1 and J Lagergren
1,3
1Unit of Oesophageal and Gastric Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
2Centro Espan ˜ol
de Investigacio ´n Farmacoepidemiolo ´gica, Madrid, Spain;
3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis
that oestrogens are protective in this respect. We carried out a nested case–control study of hormone replacement therapy (HRT)
among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency
matched by age and calendar year in the General Practitioners Research Database in the United Kingdom. Data were adjusted for
age, calendar year, tobacco smoking, alcohol consumption, body mass index, hysterectomy, and upper gastrointestinal disorders.
Among 1619563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT
compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29–0.79). This inverse association appeared to be
stronger for gastric noncardia (OR 0.34, 95% CI 0.14–0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23–2.01).
There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41–3.32).
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The male predominance is a striking and unexplained feature of
oesophageal and gastric adenocarcinomas, the sex ratio being 6:1
in both oesophageal and gastric cardia adenocarcinoma, and 2:1
in gastric noncardia adenocarcinoma (Corley and Buffler, 2001;
Parkin, 2001). The 3:1 male predominance in oesophageal
squamous-cell carcinoma is explicable by sex differences in the
prevalence of the main risk factors, that is, use of tobacco and
alcohol (Muir and McKinney, 1992; Gammon et al, 1997; Lagergren
et al, 2000). However, no corresponding sex difference in the
established risk factors for oesophageal or gastric adenocarcinoma
can explain their male predominance (EUROGAST, 1993; Moller
et al, 1994; Lagergren et al, 1999a,b; Kelley and Duggan, 2003;
Crew and Neugut, 2004). It has been hypothesised that female sex
hormones, mainly oestrogens, may explain or contribute to these
sex differences. In two prostate cancer cohort studies, of men
heavily exposed to oestrogens, there was no reduction in the risk
of oesophageal adenocarcinoma (Lagergren and Nyren, 1998),
although a decreased risk of gastric adenocarcinoma has been
reported (Lindblad et al, 2004). An increased male-to-female ratio
in gastric adenocarcinoma has been claimed as corresponding to a
10- to 15-year delay among females compared with males, possibly
due to a protective effect of female sex hormones (Sipponen and
Correa, 2002). Studies on menstrual and reproductive factors have
suggested associations with the risk of gastric adenocarcinoma
(Miller et al, 1980; Plesko et al, 1985; La Vecchia et al, 1994; Palli
et al, 1994; Heuch and Kvale, 2000; Inoue et al, 2002; Kaneko et al,
2003). Based on the hypothesis that sex hormones may be involved
in the aetiology of oesophageal or gastric adenocarcinoma,
we investigated whether hormone replacement therapy (HRT)
protects women against either of these tumours.
MATERIALS AND METHODS
General practice research database
We collected our data from the General Practice Research Database
(GPRD) in the United Kingdom (UK). This database has been
described in detail elsewhere (Garcia Rodriguez and Perez
Gutthann, 1998). The large number of person-years of follow-up
makes the GPRD a valuable resource even for the study of rare
diseases, and we have previously used this database to study risk
factors for oesophageal and gastric cancer (Lindblad et al, 2005).
The computerised information in the GPRD includes prospective
recordings of diagnoses, prescriptions of drugs, demographics,
details of every general practitioner’s (GPs) consultation, results
from laboratory tests, hospital letters, and a free text section.
Diagnoses are coded by a modification of the Oxford Medical
Information System (OXMIS) and the Read classification systems.
A drug dictionary based on data from the Prescription Pricing
Authority is used to code drugs. All prescriptions are automatically
entered into the GPRD since they are directly generated from the
participating GP’s computer, thus ensuring a complete recording.
Validation studies have shown that the GPRD data are of high
quality (Jick et al, 2003). More than 90% of all referrals are entered
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yinto the GPs computer with the specialist’s diagnosis carefully
coded (Jick et al, 1991).
Study cohort
During the study period, January 1994 through December 2001, we
identified all women in the GPRD aged between 50 and 84 years.
To be included in the study cohort, the person had to have been
enrolled with the GP for at least 2 years, and with at least 1 year
of computerised prescription history. Any person with a cancer
history recorded in the GPRD before start date was excluded.
All women in the study cohort were followed up until any of the
following events occurred: (1) detection of an oesophageal or
gastric cancer, (2) detection of any other cancer, (3) age of 85
years, (4) death, or (5) end of study period (31 December 2001),
whichever occurred first.
Identification of study participants
Within the study period, a computerised search identified 705
female subjects with a diagnosis code of oesophageal or gastric
cancer. To verify and further classify the tumours, all compu-
terised patient profiles of these patients were manually reviewed by
one investigator (ML) who was kept blinded to the exposure data.
Moreover, GPs sent additional information regarding case patients
identified by the computer (N¼346). All available information
about the tumour site and histology, as well as paper-based
information (e.g. operation and pathology reports and letters from
specialists) were reviewed. Patients were excluded if: (1) the
tumour was benign, (2) the origin of a cancer was unknown, (3)
the tumour was a metastasis, (4) the patient had another,
concurrent cancer, (5) the cancer was diagnosed before the start
date, or (6) the histological type was not adenocarcinoma or
squamous-cell carcinoma. The index date among our case patients
was set to be the date when the tumour was first recorded or when
the manual review revealed an earlier date of diagnosis. All persons
received a random date within the study period, and if it was
within that individual’s eligible person-time, she was marked as an
eligible control subject. Thereafter, we randomly selected control
subjects and their random dates were set as index dates. The
control participants were frequency matched on age (within 1
year) and same calendar year.
Drug exposure definition
Only drug exposure preceding the index date was considered in the
study. The information recorded in the GPRD, drug medications
and HRT included, could date back to the late 1980s when the
database was initiated. HRT included oral oestrogens, transdermal
oestradiol, oestradiol implants, and tibolone, and use was classified
as nonuse or ever use when there was no or any recorded use in
the database, respectively. Ever users were further categorised as
current users if use of HRT had been within the year prior to index
date, and past users if the most recent use was before that.
Duration of HRT use was calculated summing the periods of
consecutive prescriptions among ever users, grouped into two
levels: less than 3 years of treatment duration and 3 years and
more.
Statistical analyses
Unconditional logistic regression was conducted to calculate odds
ratios (ORs) with 95% confidence intervals (CIs). In multivariable
analyses, all estimates of risk were adjusted for the following
potential confounding factors: age (in 10-year intervals), calendar
year, tobacco smoking (categorised in four groups: nonsmoker,
current smoker, ex-smoker, or unknown), alcohol consumption
(categorised in five groups: 0–2, 3–15, 16–34, 434Uday
 1,o r
unknown, where one unit corresponded to 10ml or 7.9g of pure
ethanol), body mass index (BMI) (categorised in five groups: o20,
20–24.9, 25–29.9, 430kgm
 2, or unknown), hysterectomy
(categorised in two groups: yes or no), and upper gastrointestinal
disorders (categorised in two groups: never or ever). Upper
gastrointestinal disorders were defined as any recording in the
GPRD of gastrooesophageal reflux disease, peptic ulcer, dyspepsia,
or prescription of acid-suppressing drugs (proton-pump inhibitors
or H2-receptor blockers).
Ethics
The Scientific and Ethical Advisory Group (SEAG) in the UK
approved the Study.
RESULTS
Study participants
Among 1619563 person-years of follow-up, the computerised
search identified 705 women with oesophageal or gastric cancer.
After excluding 93 during the manual review for any of the
previously stated reasons, 299 were classified as oesophageal
cancer and 313 as gastric cancer. The crude incidence rate
was 18.5/100000 person-years for oesophageal cancer and
19.3/100000 person-years for gastric cancer. Oesophageal tumours
were further classified by histological type, and gastric tumours
into gastric subsite as presented in Table 1. Some basic
characteristics of the study participants are shown in Table 1.
The median ages among patients with oesophageal cancer, gastric
cancer, and control subjects were 74, 73, and 74 years, respectively,
and no striking differences were noted between the cancer
subgroups. In the youngest age group (50–59 years), gastric
cardia were over-represented and oesophageal adenocarcinomas
were under-represented. Never smokers were more frequent
among control participants than among all cancer subgroups.
The prevalence of obesity (BMI430kgm
 2) and of upper
gastrointestinal disorders was higher in oesophageal and gastric
cardia adenocarcinomas than among controls, oesophageal
squamous-cell carcinomas, and gastric noncardia adenocarcino-
mas. The median time of data collection between first drug
prescription and index date was similar between cases (2323 days)
and controls (2272 days).
HRT and oesophageal cancer
HRT was not associated with the risk of oesophageal cancer of any
histological type (OR 0.84, 95% CI 0.51–1.38) as shown in Table 2.
Multivariable analysis revealed an OR of 1.17 (95% CI 0.41–3.32)
for oesophageal adenocarcinoma among ever users of HRT
compared to nonusers. The corresponding OR for oesophageal
squamous-cell carcinoma was 0.93 (95% CI 0.40–2.16). Adjust-
ment for all covariates listed in the Materials and Methods section
did not materially change the age-adjusted risk estimates,
indicating lack of strong confounding by these covariates (Table 2).
The limited numbers of exposed cases and controls prohibited
valid analyses of duration and recency of HRT use, but the point
estimates were constant over treatment duration, while lower
estimates were found among current users (OR 0.68).
HRT and gastric cancer
Ever use of HRT was associated with a reduced risk of gastric
adenocarcinoma by 52% compared to nonusers (OR 0.48, 95% CI
0.29–0.79) (Table 3). The corresponding analysis restricted to
gastric cardia adenocarcinoma indicated a 32% reduced risk
without statistical significance (OR 0.68, 95% CI 0.23–2.01). The
66% reduced risk of gastric noncardia adenocarcinoma was
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analysis by age groups and tobacco smoking status revealed a
more pronounced inverse association in older compared to
younger women, while no difference in risk was found between
smokers and nonsmokers (Table 4). For HRT use of less than 3
years, OR was 0.34 (95% CI 0.17–0.67) of gastric cancer, while for
at least 3 years it was 0.72 (95% CI 0.38–1.38). Current users of
HRT were associated with a reduced risk of gastric cancer (OR
0.56, 95% CI 0.33–0.96) as well as past users (OR 0.25, 95% CI
0.09–0.70).
DISCUSSION
This study indicates that use of HRT was associated with a
markedly reduced risk of gastric adenocarcinoma, possibly greater
Table 1 Selected basic characteristics among case patients and control participants
Oesophageal cancer Gastric adenocarcinoma
Controls
Numbers (%) Numbers (%)
Characteristic Numbers (%) Adenocarcinoma
Squamous-cell
carcinoma
Unknown
histology Total Cardia Noncardia
Unknown
subsite Total
Total 3191 (100) 58 (100) 74 (100) 167 (100) 299 (100) 43 (100) 116 (100) 154 (100) 313 (100)
Age (years)
Median 74 years 75 years 72 years 75 years 74 years 72 years 72 years 75 years 73 years
50–59 359 (11.2) 2 (3.4) 7 (9.5) 15 (9.0) 24 (8.0) 6 (13.9) 19 (16.4) 18 (11.7) 43 (13.7)
60–69 714 (22.4) 12 (20.7) 22 (29.7) 31 (18.6) 65 (21.8) 12 (27.9) 30 (25.8) 27 (17.5) 69 (22.1)
70–79 1362 (42.7) 32 (55.2) 34 (46.0) 74 (44.3) 140 (46.8) 18 (41.9) 40 (34.5) 65 (42.2) 123 (39.3)
80–84 756 (23.7) 12 (20.7) 11 (14.8) 47 (28.1) 70 (23.4) 7 (16.3) 27 (23.3) 44 (28.6) 78 (24.9)
Tobacco smoking status
Never 1942 (60.9) 31 (53.4) 37 (50.0) 75 (44.9) 143 (47.8) 19 (44.2) 57 (49.1) 81 (52.6) 157 (50.1)
Ex-smoker 190 (6.0) 7 (12.1) 4 (5.4) 11 (6.6) 22 (7.4) 7 (16.3) 12 (10.3) 17 (11.0) 36 (11.5)
Smoker 400 (12.5) 11 (19.0) 14 (18.9) 36 (21.6) 61 (20.4) 9 (20.9) 28 (24.2) 24 (15.6) 61 (19.5)
Unknown 659 (20.6) 9 (15.5) 19 (25.7) 45 (26.9) 73 (24.4) 8 (18.6) 19 (16.4) 32 (20.8) 59 (18.9)
Alcohol consumption (Uday
 1 a)
0–2 1758 (55.1) 31 (53.4) 33 (44.6) 84 (50.3) 148 (49.5) 19 (44.2) 70 (60.3) 90 (58.5) 179 (57.2)
3–15 395 (12.4) 14 (24.1) 10 (13.5) 13 (7.8) 37 (12.4) 7 (16.3) 16 (13.8) 15 (9.7) 38 (12.1)
16–34 33 (1.0) 2 (3.5) 1 (1.4) 1 (0.6) 4 (1.3) 2 (4.6) 1 (0.9) 2 (1.3) 5 (1.6)
35+ 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 1004 (31.5) 11 (19.0) 30 (40.5) 68 (40.7) 109 (36.5) 15 (34.9) 29 (25.0) 47 (30.5) 91 (29.1)
Body mass index (kgm
 2)
Less than 20 142 (4.5) 4 (6.9) 5 (6.8) 13 (7.8) 22 (7.4) 1 (2.3) 12 (10.3) 8 (5.2) 21 (6.7)
20–24.9 812 (25.4) 10 (17.2) 20 (27.0) 31 (18.5) 61 (20.4) 12 (27.9) 35 (30.2) 46 (29.9) 93 (29.7)
25–29.9 765 (24.0) 16 (27.6) 16 (21.6) 26 (15.6) 58 (19.4) 14 (32.6) 24 (20.7) 35 (22.7) 73 (23.3)
30+ 396 (12.4) 13 (22.4) 2 (2.7) 15 (9.0) 30 (10.0) 7 (16.3) 11 (9.5) 17 (11.0) 35 (11.2)
Unknown 1076 (33.7) 15 (25.9) 31 (41.9) 82 (49.1) 128 (42.8) 9 (20.9) 34 (29.3) 48 (31.2) 91 (29.1)
Hysterectomy
No 2735 (85.7) 52 (89.7) 67 (90.5) 153 (91.6) 272 (91.0) 38 (88.4) 107 (92.2) 133 (86.4) 278 (88.8)
Yes 456 (14.3) 6 (10.3) 7 (9.5) 14 (8.4) 27 (9.0) 5 (11.6) 9 (7.8) 21 (13.6) 35 (11.2)
Upper gastrointestinal disorders
b
Never 2056 (64.4) 25 (43.1) 41 (55.4) 99 (59.3) 165 (55.2) 16 (37.2) 59 (50.9) 63 (40.9) 138 (44.1)
Ever 1135 (35.6) 33 (56.9) 33 (44.6) 68 (40.7) 134 (44.8) 27 (62.8) 57 (49.1) 91 (59.1) 175 (55.9)
aOne unit of alcohol corresponds to 10ml or 7.9g of pure ethanol.
bUpper gastrointestinal disorders were defined as any recording in the GPRD of gastrooesophageal reflux
disease, peptic ulcer, dyspepsia, or prescription of acid-suppressing drugs (proton-pump inhibitors or H2-receptor blockers).
Table 2 Odds ratios (ORs) with 95% confidence intervals (CIs) on the association between use of hormone replacement therapy (HRT) and risk of
oesophageal cancer
Control
subjects
Oesophageal
adenocarcinoma
Oesophageal squamous-cell
carcinoma
Oesophageal cancer of
unknown histology Total oesophageal cancer
Exposure N (%) N (%) OR (95% CI) N (%) OR (95% CI) N (%) OR (95% CI) N (%) OR (95% CI)
HRT
Never 2846 (89.2) 53 (91.4) 1.00 (reference) 66 (89.2) 1.00 (reference) 157 (94.0) 1.00 (reference) 276 (92.3) 1.00 (reference)
Ever 345 (10.8) 5 (8.6) 1.27 (0.46–3.48)
a 8 (10.8) 0.94 (0.42–2.15)
a 10 (6.0) 0.56 (0.28–1.15)
a 23 (7.7) 0.78 (0.48–1.26)
a
1.17 (0.41–3.32)
b 0.93 (0.40–2.16)
b 0.65 (0.31–1.37)
b 0.84 (0.51–1.38)
b
aORs adjusted only for age.
bORs adjusted for age, calendar year, tobacco smoking, alcohol consumption, body mass index, hysterectomy, and upper gastrointestinal disorders.
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was observed for oesophageal adenocarcinoma.
The low exposure prevalence of HRT and the low incidence of
oesophageal and gastric adenocarcinoma in females might explain
the lack of previous studies of this topic. Our large sample size was
necessary to provide informative results. The reported incidence of
adenocarcinoma of the oesophagus and gastric cardia in the UK is
higher than that of any other country worldwide (Berrino et al,
1999). Still, the limited number of exposed affected women in our
study prohibited extensive subgroup analyses, including the
influence of duration of HRT or HRT regimen. The prospective
exposure assessment, that is, before cancer occurrence, is the main
strength of the study. Also, our manual review of all case patients
should reduce misclassification of cancer, although a number of
missing values remained on specific histology and subsite. The
risk of tumour misclassification was highest for gastric cardia
adenocarcinoma, so our estimates for this site are more prone to
such error. The lack of a strong inverse association between HRT
and oesophageal cancers in our study provides some reassurance
that selection bias does not explain the inverse association with
gastric cancer. Any remaining tumour misclassification should not
be associated with HRT use and could therefore, at the most, dilute
our results toward null. Several potential confounding factors were
considered, but not Helicobacter pylori infection or socioeconomic
status. H pylori infection, an established risk factor for gastric
noncardia adenocarcinoma (Uemura et al, 2001), has also been
reported to be associated with a reduced risk of oesophageal
adenocarcinoma, but not of gastric cardia adenocarcinoma
(Hansson et al, 1993; Ye et al, 2004). H pylori infection is
positively associated with low social class (Boffetta, 1997), which in
turn could be associated with reduced HRT use. As we could not
adjust for these factors, our results could be distorted by residual
confounding. However, our lack of association between HRT
and oesophageal squamous-cell carcinoma, well known to be
associated with low social class, does not support a major role for
confounding by social class.
Few studies of hormonal factors and risk of oesophageal
adenocarcinoma have been published. Our lack of a clear effect
of HRT on the risk of oesophageal cancer is in contrast to a study
which found that use of HRT, oral contraceptives, and age at
menopause were all inversely related with the risk of oesophageal
squamous-cell carcinoma (Gallus et al, 2001). The small sample
size, the lack of data regarding oesophageal adenocarcinoma, and
the retrospective exposure assessment in this study might explain
the differences from our study. In line with our current findings
is the lack of association between oestrogen treatment and
oesophageal adenocarcinoma in our cohort study of prostate
cancer patients (Lagergren and Nyren, 1998). There have been
somewhat more studies of hormonal influences on gastric cancer.
Our findings accord with the age-group-specific male-to-female
ratio unique for gastric adenocarcinomas (Sipponen and Correa,
2002). In line with our findings is the decreased risk of gastric
adenocarcinoma in our cohort of oestrogen-exposed prostate
cancer patients (Lindblad et al, 2004) and a protective trend by
HRT on gastric cancer (La Vecchia et al, 1994; Fernandez et al,
2003). However, results from studies of menstrual, reproductive
factors, and parity and risk of gastric cancer are partly conflicting
(Miller et al, 1980; Plesko et al, 1985; La Vecchia et al, 1994; Palli
et al, 1994; Heuch and Kvale, 2000; Inoue et al, 2002; Kaneko et al,
2003). A longer period of fertility among females, that is, the
time from menarche to menopause, increases the lifetime exposure
to endogenous oestrogens and has been suggestive of a reduced
gastric cancer risk (La Vecchia et al, 1994; Palli et al, 1994; Inoue
et al, 2002; Kaneko et al, 2003), although a lack of such association,
and an inverse association with age at menarche has also been
reported (Heuch and Kvale, 2000). Multiparity has been associated
with both an increased risk of gastric cancer in several studies
(Plesko et al, 1985; La Vecchia et al, 1994; Palli et al, 1994; Heuch
and Kvale, 2000; Inoue et al, 2002), and a reduced risk of gastric
cancer (Kaneko et al, 2003). Experimental data in rats (Furukawa
et al, 1982; Campbell-Thompson et al, 1999) suggest that oestrogen
may prevent gastric cancer development.
The inverse association of HRT was particularly strong for
gastric noncardia adenocarcinoma. It is not surprising that the
associations between HRT and subsites of adenocarcinoma of the
oesophagus, gastric cardia, and gastric noncardia differ. Marked
differences in risk factor profiles exist between these tumour sites
(Fuchs and Mayer, 1995; Enzinger and Mayer, 2003). The evidence
of hormonal influence is strongest for gastric noncardia adeno-
carcinoma. The seemingly stronger protective effect of HRT among
older women, who are more likely to have longer exposures, might
suggest that a longer dose–response relation exists. This, however,
could not be confirmed though our numbers were limited.
Table 3 Odds ratios (ORs) with 95% confidence intervals (CIs) on the association between use of hormone replacement therapy (HRT) and risk of
gastric adenocarcinoma
Control
subjects
Gastric cardia
adenocarcinoma
Gastric noncardia
adenocarcinoma
Unknown subsite of gastric
adenocarcinoma
Total gastric
adenocarcinoma
Exposure N (%) N (%) OR (95% CI) N (%) OR (95% CI) N (%) OR (95% CI) N (%) OR (95% CI)
HRT
Never 2846 (89.2) 38 (88.4) 1.00 (reference) 109 (94.0) 1.00 (reference) 143 (92.9) 1.00 (reference) 290 (92.6) 1.00 (reference)
Ever 345 (10.8) 5 (11.6) 0.85 (0.30–2.44)
a 0.34 (0.15–0.77)
a 0.61 (0.30–1.21)
a 0.51 (0.32–0.83)
a
0.68 (0.23–2.01)
b 7 (6.0) 0.34 (0.14–0.78)
b 11 (7.1) 0.55 (0.27–1.12)
b 23 (7.4) 0.48 (0.29–0.79)
b
aORs adjusted for age.
bORs adjusted for age, calendar year, tobacco smoking, alcohol consumption, body mass index, hysterectomy, and upper gastrointestinal disorders.
Table 4 Odds ratios (ORs) with 95% confidence interval (CI) on the
association between use of hormone replacement therapy and gastric
adenocarcinoma stratified by age and tobacco smoking categories
Gastric adenocarcinoma
Stratified category OR (95% CI)
a
Age (years)
50–59 0.53 (0.25–1.13)
(Number of exposed cases/controls) (16/173)
60+ 0.38 (0.18–0.84)
(Number of exposed cases/controls) (7/172)
Tobacco smoking status OR (95% CI)
b
Never 0.53 (0.26–1.08)
(Number of exposed cases/controls) (11/214)
Ever 0.52 (0.24–1.12)
(Number of exposed cases/controls) (13/107)
aAdjusted for calendar year, tobacco smoking, alcohol consumption, body mass
index, hysterectomy, and upper gastrointestinal disorders.
bAdjusted for age, calendar
year, alcohol consumption, body mass index, hysterectomy, and upper gastro-
intestinal disorders.
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cancer is unknown. Oestrogen receptors have been identified in
normal and cancer tissue of the oesophagus and stomach
(Korenaga et al, 1998; Akgun et al, 2002; Matsuyama et al,
2002). Oestrogens may prevent colon cancer by decreasing bile
acid concentration or by direct effects on the colonic mucosa, as
suggested by in vitro studies (McMichael and Potter, 1980; Nanda
et al, 1999), and this may also apply in gastric adenocarcinoma.
The fact that the protective effect of HRT is stronger for noncardia
tumours, that is, those closer to the bile duct, might support
this possibility. Women have a lower gastric acid secretion than
men, and oestrogen reduces acid gastric secretion and the mass of
parietal cells in rats (Adeniyi, 1991), so oestrogen may affect
gastric acid production.
The relation between HRT and gastric adenocarcinoma warrants
further research before any clinical implications would be
appropriate, particularly given the initial enthusiasm about the
seemingly protective effect of HRT against cardiovascular disease,
which was later not supported (Nelson et al, 2002).
In conclusion, our large study using a prospective database
indicates that HRT is associated with a risk reduction of gastric
adenocarcinoma, particularly of the noncardia site, while no
association was found for oesophageal adenocarcinoma. As we
could not control for H. pylori infection or social class, our
findings must be regarded as tentative. If oestrogens truly and
strongly protect against the development of gastric adenocarci-
noma, its male predominance may be partly explained by the
endogenous oestrogen exposure during women’s fertile years.
Further research on the potential benefits and harm of sex
hormones in relation to gastric cancer may be warranted.
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